MSD

News

One in five men carries HPV linked to cancer

Researchers have estimated that almost one in three men worldwide is infected with at least one genital human papillomavirus (HPV) strain, and one in five is harbouring st

News

Keytruda backed for 'basket' of new cancers via NHS

The UK's cost-effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instab

News

FDA clears J&J's 2-in-1 tablet for prostate cancer

Johnson & Johnson has been given FDA approval for Akeega, a combination tablet for first-line treatment of adults with BRCA-positive metastatic castration-resistant pr

News

MSD, Moderna start phase 3 trial of mRNA cancer jab

MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou

News

AstraZeneca, MSD raise prostate cancer awareness with 'Never...

A new global prostate cancer awareness campaign developed by biopharmaceutical companies AstraZeneca (AZ) and Merck & Co.

Patients

Patient engagement strategies: the pharmaphorum podcast

This episode of the pharmaphorum podcast is the first in an occasional series focused on patient engagement that’s being led by Mark Duman, a clinician, consultant and patient advocate.

One in five men carries HPV linked to cancer

Keytruda backed for 'basket' of new cancers via NHS

FDA clears J&J's 2-in-1 tablet for prostate cancer

MSD, Moderna start phase 3 trial of mRNA cancer jab

AstraZeneca, MSD raise prostate cancer awareness with 'Never...

Patient engagement strategies: the pharmaphorum podcast

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

MSD

Editor's Picks